1. Home
  2. PNW vs PRAX Comparison

PNW vs PRAX Comparison

Compare PNW & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pinnacle West Capital Corporation

PNW

Pinnacle West Capital Corporation

HOLD

Current Price

$99.63

Market Cap

11.1B

Sector

Utilities

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$292.64

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNW
PRAX
Founded
1985
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.1B
9.6B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
PNW
PRAX
Price
$99.63
$292.64
Analyst Decision
Hold
Strong Buy
Analyst Count
13
15
Target Price
$97.25
$572.13
AVG Volume (30 Days)
1.2M
328.0K
Earning Date
04-30-2026
05-01-2026
Dividend Yield
3.69%
N/A
EPS Growth
N/A
N/A
EPS
5.05
N/A
Revenue
$5,339,939,000.00
N/A
Revenue This Year
$5.24
N/A
Revenue Next Year
$6.67
$6,395.88
P/E Ratio
$19.51
N/A
Revenue Growth
4.20
N/A
52 Week Low
$85.32
$26.70
52 Week High
$103.97
$354.87

Technical Indicators

Market Signals
Indicator
PNW
PRAX
Relative Strength Index (RSI) 52.20 42.38
Support Level $86.96 $289.02
Resistance Level $103.59 $322.32
Average True Range (ATR) 1.77 16.26
MACD -0.57 -0.68
Stochastic Oscillator 40.86 17.75

Price Performance

Historical Comparison
PNW
PRAX

About PNW Pinnacle West Capital Corporation

Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases 6.5 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: